This week's top stories: AI insights, data quality and drug resistance
📈 Trending news from the industry
In this in-depth Q&A, Mutlu Dogruel , Vice President of AI at Cresset shares his insights surrounding chatbots, retrieval augmented generation and AI hallucinations, to open up new possibilities for innovation in pharmaceutical research. Read more >>
In this four-part series, Dr Raminderpal Singh discusses the challenges surrounding limited data quality and offers some pragmatic solutions. In this fourth article, he talks to John Conway, Chief Visioneer Officer at 20/15 Visioneers for an expert perspective. Read more >>
Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways.
Researchers at Okayama University have investigated the application of anti-PD-1 autoantibody as a biomarker candidate for hepatocellular carcinoma (HCC).
HCC is the most commonly type of liver cancer and the fourth leading cause of cancer-related death globally. One treatment for patients with an advanced form of HCC involves a combination of the drugs atezolizumab and bevacizumab, referred to as Atezo/Bev therapy, which is typically recommended as the first treatment for patients with liver cancer. Despite this, there are no reliable markers that can be used to predict its effectiveness.
Scientists at Brigham and Women’s Hospital have developed a spray which provides broad-spectrum protection from respiratory infections by COVID-19, influenza, everyday cold viruses, and pneumonia-causing bacteria. This may reduce respiratory diseases and safeguard public health if it can be validated in humans. Read more >>
💻 Webinar of the week
Join our upcoming webinar to gain insights into the latest advancements in HIV vaccine development, including challenges, breakthroughs and future directions in the field.
We will also examine the significance of emerging technologies and discuss recent promising preclinical results, highlighting how these findings could translate into clinical trials. Furthermore, our experts will elucidate the present trends in the field and forecast potential advancements that we could see in the next five to 10 years.
🎧 Listen up!
🎙️ New Podcast: Scaling genetic medicine with tRNA
Tune in to this episode which explores how engineered tRNAs could treat thousands of rare diseases and cancers that share the same mutation.
This conversation features Michelle Werner, CEO of Alltrna and CEO-Partner at Flagship Pioneering, and Caroline Köhrer, Vice President, Discovery Platform at Alltrna.
🖊️ Sign up for free!
Sign up here to stay ahead of all the latest breaking news, expert insights and the newest trends in global drug discovery.
Drug Target Review is an essential multimedia resource which is trusted and recognised globally of researchers and scientific leaders who cover the most up-to-date innovations, and cutting edge technologies in the industry.